Eli Lilly (LLY) Q3 2026 Earnings Call Transcript
On its third-quarter 2026 earnings call, Eli Lilly reported revenue growth of 39%, attributed to demand for its obesity drugs and strong international growth.
fool.com ·
Pre-market
$1,424.48
-over selected period
+$15.10 (+1.07%)since US close
Price differences before fees and execution costs. Compare prices
On its third-quarter 2026 earnings call, Eli Lilly reported revenue growth of 39%, attributed to demand for its obesity drugs and strong international growth.
fool.com ·
Benzinga reports Eli Lilly beat third-quarter estimates on Mounjaro and Zepbound growth, with 2026 revenue guidance rising to $92 billion.
benzinga.com ·
Eli Lilly CEO David Ricks said middle-income consumers are driving what he called the largest new category expansion in pharma, according to Benzinga's report on the company's latest earnings.
benzinga.com ·
Eli Lilly raised its revenue guidance to $91 billion to $92 billion from $85 billion to $87 billion, its third outlook increase this year, as quarterly sales climbed 39%.
qz.com ·
Seeking Alpha reports Mounjaro sales reached $10.7B in the third quarter, while Jardiance rose 64.5% year over year to $1.58B.
seekingalpha.com ·
Hold LLYc in a Mo smart wallet on Base that you control.
Send LLYc to another Mo user for free, or transfer to any compatible Base wallet near-instantly.